Announced details
Mental health, return-to-work support, occupational health and healthcare
Approximately 0.2 mL of self-collected blood. The MHT Group's approximately 4,000 corporate clients and employee base numbering several million are identified as potential targets for future commercialization.
インクルード is a wholly owned subsidiary of the MHT Group. aiwell is the counterparty to the joint research agreement. MHT will cooperate in commercializing the research results. インクルード will select study participants, obtain their consent, collect information and provide blood collection sites and other resources, while aiwell will oversee the research plan, ethics review, blood collection technology support, analysis and compilation of the results.
インクルード株式会社 is based in Shibuya, Tokyo, and its representative director and president is Ozaki Koichi (尾崎浩一). It operates Neuro Rework, return-to-work support, employment transition support and independent living training facilities for people on leave from work or unemployed due to depression, adjustment disorders, developmental disorders and other conditions. It is a wholly owned subsidiary of the MHT Group. aiwell株式会社 is based in Minato, Tokyo, and its representative director is Mabuchi Hiroyuki (馬渕浩幸). It is a venture company certified by the Institute of Science Tokyo and builds services and systems based on protein analysis technology using small-volume blood samples.
Patent Nos. 7113446, 7215682 and 7670286 (held by aiwell)
1-2-14 Shibadaimon, Minato-ku, Tokyo (aiwell); 4th Floor, 35th Arai Building, 1-1-3 Shibuya, Shibuya-ku, Tokyo (インクルード); 4th Floor, Tokai Akasaka Building, 3-16-11 Akasaka, Minato-ku, Tokyo (MHT)
Future commercialization and service development based on the results of this research are under consideration. No specific financial impact was provided.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | aiwell ProteoSIGN, Neuro Rework (return-to-work support program) |
| Counterparty | インクルード株式会社, aiwell株式会社 |
| Counterparty overview | インクルード株式会社 is based in Shibuya, Tokyo, and its representative director and president is Ozaki Koichi (尾崎浩一). It operates Neuro Rework, return-to-work support, employment transition support and independent living training facilities for people on leave from work or unemployed due to depression, adjustment disorders, developmental disorders and other conditions. It is a wholly owned subsidiary of the MHT Group. aiwell株式会社 is based in Minato, Tokyo, and its representative director is Mabuchi Hiroyuki (馬渕浩幸). It is a venture company certified by the Institute of Science Tokyo and builds services and systems based on protein analysis technology using small-volume blood samples. |
| Relationship with the Company | インクルード is a wholly owned subsidiary of the MHT Group. aiwell is the counterparty to the joint research agreement. MHT will cooperate in commercializing the research results. インクルード will select study participants, obtain their consent, collect information and provide blood collection sites and other resources, while aiwell will oversee the research plan, ethics review, blood collection technology support, analysis and compilation of the results. |
| Contract Date | 8 October 2026 (the date of the announcement that the joint research agreement had been signed; the agreement date was not specified) |
| Applicable area | Mental health, return-to-work support, occupational health and healthcare |
| Registration number and expiry date | Patent Nos. 7113446, 7215682 and 7670286 (held by aiwell) |
| Location | 1-2-14 Shibadaimon, Minato-ku, Tokyo (aiwell); 4th Floor, 35th Arai Building, 1-1-3 Shibuya, Shibuya-ku, Tokyo (インクルード); 4th Floor, Tokai Akasaka Building, 3-16-11 Akasaka, Minato-ku, Tokyo (MHT) |
| Quantitative Effects | Approximately 0.2 mL of self-collected blood. The MHT Group's approximately 4,000 corporate clients and employee base numbering several million are identified as potential targets for future commercialization. |
| Impact on Business Performance | Future commercialization and service development based on the results of this research are under consideration. No specific financial impact was provided. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Mental health assessments often rely on subjective indicators such as interviews, creating demand for objective indicators, or biomarkers.